These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 23128399

  • 21. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.
    Gupta S, Weinstock-Guttman B.
    Expert Opin Biol Ther; 2014 Jan; 14(1):115-26. PubMed ID: 24289270
    [Abstract] [Full Text] [Related]

  • 22. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.
    Anton R, Haas M, Arlett P, Weise M, Balabanov P, Mazzaglia G, Prieto L, Keller-Stanislawski B, Raine J.
    Clin Pharmacol Ther; 2017 Aug; 102(2):283-289. PubMed ID: 28001298
    [Abstract] [Full Text] [Related]

  • 23. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.
    Planas R, Jelčić I, Schippling S, Martin R, Sospedra M.
    Eur J Immunol; 2012 Mar; 42(3):790-8. PubMed ID: 22144343
    [Abstract] [Full Text] [Related]

  • 24. [Natalizumab in multiple sclerosis: unclear patient benefits].
    Schipper JP.
    Ned Tijdschr Geneeskd; 2007 Apr 14; 151(15):852-5. PubMed ID: 17472115
    [Abstract] [Full Text] [Related]

  • 25. PML: underdiagnosed in MS patients on natalizumab.
    Steiner I.
    Lancet Neurol; 2010 Jun 14; 9(6):564; author reply 564-5. PubMed ID: 20494319
    [No Abstract] [Full Text] [Related]

  • 26. MS drug back on market under restricted program.
    FDA Consum; 2006 Jun 14; 40(4):7. PubMed ID: 17243280
    [No Abstract] [Full Text] [Related]

  • 27. [Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?].
    Warnke C, Adams O, Gold R, Hartung HP, Hohlfeld R, Wiendl H, Kieseier BC.
    Nervenarzt; 2011 Apr 14; 82(4):475-80. PubMed ID: 21240604
    [Abstract] [Full Text] [Related]

  • 28. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B, Kappos L.
    Neurodegener Dis; 2008 Apr 14; 5(1):16-22. PubMed ID: 18075270
    [Abstract] [Full Text] [Related]

  • 29. Natalizumab-induced PML: can the beast be tamed?
    Hohlfeld R.
    J Neurol Neurosurg Psychiatry; 2013 Oct 14; 84(10):1065. PubMed ID: 23475818
    [No Abstract] [Full Text] [Related]

  • 30. Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy.
    Diotti RA, Mancini N, Clementi N, Sautto G, Moreno GJ, Criscuolo E, Cappelletti F, Man P, Forest E, Remy L, Giannecchini S, Clementi M, Burioni R.
    Antiviral Res; 2014 Aug 14; 108():94-103. PubMed ID: 24909571
    [Abstract] [Full Text] [Related]

  • 31. The return of natalizumab: weighing benefit against risk.
    Goodin D.
    Lancet Neurol; 2006 May 14; 5(5):375-7. PubMed ID: 16632301
    [No Abstract] [Full Text] [Related]

  • 32. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
    Fine AJ, Sorbello A, Kortepeter C, Scarazzini L.
    Ann Neurol; 2014 Jan 14; 75(1):108-15. PubMed ID: 24242357
    [Abstract] [Full Text] [Related]

  • 33. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
    Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J.
    Mult Scler; 2012 Jun 14; 18(6):899-901. PubMed ID: 22183929
    [Abstract] [Full Text] [Related]

  • 34. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis.
    Foley J.
    Am J Manag Care; 2010 Jun 14; 16(6 Suppl):S178-83. PubMed ID: 20615054
    [Abstract] [Full Text] [Related]

  • 35. Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).
    Sørensen PS.
    Mult Scler; 2012 Aug 14; 18(8):1070-2. PubMed ID: 22807471
    [No Abstract] [Full Text] [Related]

  • 36. How Tysabri survived.
    Huggett B.
    Nat Biotechnol; 2009 Nov 14; 27(11):986. PubMed ID: 19898447
    [Abstract] [Full Text] [Related]

  • 37. Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
    Krämer J, Tenberge JG, Kleiter I, Gaissmaier W, Ruck T, Heesen C, Meuth SG.
    PLoS One; 2017 Nov 14; 12(4):e0174858. PubMed ID: 28406921
    [Abstract] [Full Text] [Related]

  • 38. Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk.
    Hartung HP, Mares J, Meuth SG, Berger T.
    Neurotherapeutics; 2021 Jul 14; 18(3):1654-1656. PubMed ID: 34480292
    [No Abstract] [Full Text] [Related]

  • 39. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
    Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, Gold R.
    N Engl J Med; 2009 Sep 10; 361(11):1075-80. PubMed ID: 19741228
    [Abstract] [Full Text] [Related]

  • 40. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis.
    Bennett JL.
    Neurol Res; 2006 Apr 10; 28(3):291-8. PubMed ID: 16687056
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.